148 related articles for article (PubMed ID: 37858454)
1. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
Herlemann A; Cowan JE; Washington SL; Wong AC; Broering JM; Carroll PR; Cooperberg MR
Eur Urol; 2024 Jun; 85(6):565-573. PubMed ID: 37858454
[TBL] [Abstract][Full Text] [Related]
2. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
3. Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens.
Aas K; Berge V; Myklebust TÅ; Fosså SD
Eur Urol Open Sci; 2021 Apr; 26():55-63. PubMed ID: 34337508
[TBL] [Abstract][Full Text] [Related]
4. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
5. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
6. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity.
Nepple KG; Stephenson AJ; Kallogjeri D; Michalski J; Grubb RL; Strope SA; Haslag-Minoff J; Piccirillo JF; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Kibel AS
Eur Urol; 2013 Sep; 64(3):372-8. PubMed ID: 23506834
[TBL] [Abstract][Full Text] [Related]
7. Functional Outcomes After Localized Prostate Cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract][Full Text] [Related]
8. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
9. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
10. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
[TBL] [Abstract][Full Text] [Related]
12. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cooperberg MR; Vickers AJ; Broering JM; Carroll PR
Cancer; 2010 Nov; 116(22):5226-34. PubMed ID: 20690197
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
15. A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer.
Fankhauser CD; Parry MG; Ali A; Cowling TE; Nossiter J; Sujenthiran A; Berry B; Morris M; Aggarwal A; Payne H; van der Meulen J; Clarke NW
Eur J Cancer; 2023 Mar; 181():70-78. PubMed ID: 36641896
[TBL] [Abstract][Full Text] [Related]
16. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
[TBL] [Abstract][Full Text] [Related]
17. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
Patel SA; Ma TM; Wong JK; Stish BJ; Dess RT; Pilar A; Reddy C; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Tran PT; Krauss DJ; Abu-Isa EI; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; DeWeese TL; Tilki D; Ciezki JP; Karnes RJ; Nickols NG; Rettig MB; Feng FY; Berlin A; Tward JD; Davis BJ; Reiter RE; Boutros PC; Romero T; Horwitz EM; Tendulkar RD; Steinberg ML; Spratt DE; Xiang M; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):645-653. PubMed ID: 36179990
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
Kishan AU; Shaikh T; Wang PC; Reiter RE; Said J; Raghavan G; Nickols NG; Aronson WJ; Sadeghi A; Kamrava M; Demanes DJ; Steinberg ML; Horwitz EM; Kupelian PA; King CR
Eur Urol; 2017 May; 71(5):766-773. PubMed ID: 27452951
[TBL] [Abstract][Full Text] [Related]
19. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
Tilki D; Chen MH; Wu J; Huland H; Graefen M; Braccioforte M; Moran BJ; D'Amico AV
JAMA Oncol; 2019 Feb; 5(2):213-220. PubMed ID: 30452521
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
